$4.74
4.24% yesterday
Nasdaq, Oct 17, 10:15 pm CET
ISIN
US76200L3096
Symbol
RZLT

Rezolute Inc Stock price

$4.74
-0.25 5.01% 1M
+1.50 46.30% 6M
+3.75 377.58% YTD
+3.76 383.67% 1Y
-1.92 28.83% 3Y
-2.66 35.95% 5Y
-60.26 92.71% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-0.21 4.24%
ISIN
US76200L3096
Symbol
RZLT

Key metrics

Market capitalization $265.10m
Enterprise Value $140.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-70.42m
Free Cash Flow (TTM) Free Cash Flow $-57.37m
Cash position $126.87m
EPS (TTM) EPS $-1.33
P/E forward negative
Short interest 3.35%
Show more

Is Rezolute Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Rezolute Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Rezolute Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Rezolute Inc forecast:

Buy
88%
Hold
13%

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
89% 89%
-
-0.04 -0.04
89% 89%
-
- Selling and Administrative Expenses 15 15
28% 28%
-
- Research and Development Expense 56 56
27% 27%
-
-70 -70
27% 27%
-
- Depreciation and Amortization 0.04 0.04
89% 89%
-
EBIT (Operating Income) EBIT -70 -70
26% 26%
-
Net Profit -68 -68
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rezolute Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rezolute Inc Stock News

Neutral
GlobeNewsWire
28 days ago
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
Positive
Reuters
about one month ago
Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.
Neutral
GlobeNewsWire
about one month ago
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Nevan Elam
Employees 59
Founded 2010
Website www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today